| 1.27 -0.01 (-0.78%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.7 |
1-year : | 1.86 |
| Resists | First : | 1.45 |
Second : | 1.6 |
| Pivot price | 1.45 |
|||
| Supports | First : | 1.23 |
Second : | 1.02 |
| MAs | MA(5) : | 1.33 |
MA(20) : | 1.45 |
| MA(100) : | 1.34 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 4.7  |
D(3) : | 3.7 |
| RSI | RSI(14): 33 |
|||
| 52-week | High : | 2.2 | Low : | 1.12 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MNOV ] has closed above bottom band by 0.7%. Bollinger Bands are 77.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.32 | 1.32 - 1.33 |
| Low: | 1.2 - 1.22 | 1.22 - 1.23 |
| Close: | 1.25 - 1.28 | 1.28 - 1.29 |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Thu, 18 Dec 2025
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
Thu, 18 Dec 2025
D. Boral Capital Reaffirms Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
Thu, 18 Dec 2025
MediciNova, Inc. Completes Patient Enrollment in Phase 2 OXTOX Study for MN-166 in Metastatic Colorectal Cancer Patients - Quiver Quantitative
Wed, 12 Nov 2025
MEDICINOVA INC SEC 10-Q Report - TradingView — Track All Markets
Thu, 06 Nov 2025
MediciNova, Inc. Wins Contract Research and Development Innovation Award at BioTech Breakthrough Awards - Quiver Quantitative
Thu, 06 Nov 2025
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 4.208e+007 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 756 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.335e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 741.6 % |
| Return on Equity (ttm) | -15.9 % |
| Qtrly Rev. Growth | 257920 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -50.55 |
| EBITDA (p.s.) | 54791.7 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.67 |
| Dividend | 0 |
| Forward Dividend | 465790 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|